Langley, R., Thaci, D., Blauvelt, A. ., Tsai, T.-F., Miller, M. ., Yu, J., Shen, Y.-K. ., You, Y., Yang, Y.-W., Papp, K. ., Puig, L., & Foley, P. (2022). Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, 6(2), s1. https://doi.org/10.25251/skin.6.supp.1